<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650529</url>
  </required_header>
  <id_info>
    <org_study_id>G-NUH</org_study_id>
    <nct_id>NCT04650529</nct_id>
  </id_info>
  <brief_title>Gyeongsang National University Hospital Registry</brief_title>
  <acronym>GNUH</acronym>
  <official_title>G-NUH (Gyeongsang National University Hospital) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The G-NUH registry is a two-center, real-world registry of percutaneous coronary intervention&#xD;
      in patients with significant coronary artery disease. From January 2010, PCI-treated patients&#xD;
      from Gyeonsang National University Hospitals (Jinju &amp; Changwon) were enrolled in this&#xD;
      registry.&#xD;
&#xD;
      The aim of this registry is to investigate long-term clinical outcomes and predictors of&#xD;
      adverse outcomes after percutaneous coronary intervention from the academic hospitals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the G-NUH registry, the investigators have collected and measured multiple hemostatic,&#xD;
      physiologic and laboratory measurements (on-admission &amp; 1-month) and questionnarred from&#xD;
      PCI-treated patients. This registry will focus on the impacts of these parameters on&#xD;
      long-term clinical outcomes from East Asian patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>up to 10 years</time_frame>
    <description>the composite of cardiovascular death, myocardial infarction or stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Mortality related with cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Fatal &amp; non-fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Ischemic &amp; hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>up to 10 years</time_frame>
    <description>target-lesion, target-vessel vs. nontarget-vessel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>up to 10 years</time_frame>
    <description>BARC type 3-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Thrombotic events in &amp; near to stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISR</measure>
    <time_frame>up to 10 years</time_frame>
    <description>in-stent restenosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to platelet function</measure>
    <time_frame>up to 10 years</time_frame>
    <description>VerifyNow assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to global hemostasis assay</measure>
    <time_frame>up to 10 years</time_frame>
    <description>thromboelastography (TEG: R, alpha angle, MA and LY30)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to hemostatic biomarkers</measure>
    <time_frame>up to 10 years</time_frame>
    <description>hs-CRP, fibrinogen, D-dimer, NT-proBNP, lipid battery</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to cardiac contractility</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Echocardiography: LV EF, E/A, TR Vmax, LAVI</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to physiologic index</measure>
    <time_frame>up to 10 years</time_frame>
    <description>fractional flow reserve (FFR), coronary flow reserve (CFR) and the index of microvascular resistance (IMR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of MACE according to 1-month bleeding &amp; dyspnea episodes</measure>
    <time_frame>up to 10 years</time_frame>
    <description>Qestionnarres for bleeding, dyspnea, side effects</description>
  </other_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Hemostatic Disorder</condition>
  <condition>Blood Clot</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent, ballooning</intervention_name>
    <description>DES, BMS, BRS, DEB, and POBA can be used for PCI</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      After we receive patients' approval, their blood would be collected before PCI. The blood&#xD;
      will be stored in Biobank (Gyeongsang National University Hospital).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The GNUH registry is focused on clinical impact of multiple hemostatic, physiologic and&#xD;
        laboratory measurements on CAD patients treated with PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Significant coronary artery disease&#xD;
&#xD;
          -  Treated with PCI&#xD;
&#xD;
          -  Multiple hemostatic or physiologic measurements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically treated cases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Changwon Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Sin Koh, MD, PhD</last_name>
    <phone>82-10-8544-0175</phone>
    <email>kjs0175@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changwon Gyeongsang National University Hospital</name>
      <address>
        <city>Changwon</city>
        <state>Gyeongsangnam-do</state>
        <zip>51472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongwhi Park, MD PhD</last_name>
      <phone>82-10-2173-7214</phone>
      <email>angio2000@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyeonsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeonsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Sin Koh, MD, PhD</last_name>
      <phone>82-10-8544-0175</phone>
      <email>kjs0175@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://link.springer.com/article/10.1007/s11239-020-02103-w</url>
    <description>Analysis from the G-NUH registry</description>
  </link>
  <results_reference>
    <citation>Bae JS, Ahn JH, Jang JY, Cho SY, Kang MG, Kim KH, Park HW, Koh JS, Park Y, Hwang SJ, Kwak CH, Hwang JY, Tantry US, Gurbel PA, Jeong YH. The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. J Thromb Thrombolysis. 2020 Nov;50(4):969-981. doi: 10.1007/s11239-020-02103-w.</citation>
    <PMID>32279217</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gyeongsang National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Hoon Jeong</investigator_full_name>
    <investigator_title>Director, Cardiovascular Center</investigator_title>
  </responsible_party>
  <keyword>East Asian Paradox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>This registry would be shared with other researchers in terms of whole collected data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

